Alzheimer’s Disease

July 22, 2019
July 22, 2019
Troriluzole
Troriluzole
Phase 2/3 of clinical trial being enrolled.

Yahoo Finance
[Not supported by viewer]



Creator: Biohaven Pharmaceuticals

Website: T2PROTECT.ORG

Summary:  A drug that modulates glutamate, a neurotransmitter that may contribute to Alzheimer’s. The goal is to improve memory and cognitive problems as well as reduce the progression of the disease.



[Not supported by viewer]